$4.59
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 702 full-time employees. The company went IPO on 2021-07-23. The firm is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
Country

US

CEO

Dr. Wenbin Jiang

IPO date

2021

Employees

678

ISIN

US23285D1090

Key stats

Open

$4.40

Volume

710.97K

Market cap

$566.94M

Prev. close

$4.59

Impl / hst vl

-

Open interest

$0.00

$4.30

Day’s Range

$4.59

$3.31

52W Range

$6.04

Valuation

55
Valuation score
Fairly Valued
P/E
-
P/S
2.78
P/B
1.73
Current ratio
4.69
Debt / Equity
-0.17
ROE
-20.77%
Gross margin
48.16%
Income growth
-57.20%
FCF growth
173.67

Analysts estimates

Consensus rating
Buy

The average rating from top 4 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$5.80
The top 6 analysts forecasts that 12-month price may increase by 26.39%, with a low of $4.80 and a high of $7.88
$4.80
Low
$5.80
Avg
$7.88
High
Current price

Earnings

Q1 ‘26 revenue
$44.14M
Q1 ‘26 net income
-$18.87M
Revenue
Net income
Previous EPS
-$0.15
Estimate EPS
-$0.09
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply